Home › NCT07376889
Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia
RecruitingPhase 4
COMBAT-SAB: Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria:
* Age ≥18 years
* Alive and admitted to an Intermountain Health (IH) hospital acute care unit at enrollment
* Initial positive blood culture with either methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-susceptible Staphylococcus aureus (MSSA), collected:
1. on or during the index admission to an IH hospital, or
2. in an ambulatory setting (laboratory, clinic or emergency department) within 48 hours of the index admission, or
3. at a non-IH network hospital within 24 hours of subsequent transfer to an IH hospital
Exclusion Criteria:
* Patient requests that patient health data not be included in the analysisAbout the study
The purpose of this study is to see if, in selected patients with a serious bacterial infection of the bloodstream, treating the bacterial infection with a combination of antibiotics is more effective than treating the infection with a single antibiotic. Participants must have blood cultures which are positive for a certain type of bacteria.
What is being tested
- Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB) (drug)
- Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB) (drug)
- Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB) (drug)
- Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB) (drug)
Sponsor: Intermountain Health Care, Inc. · Participants: 2,096 · Started: Feb 1, 2026
Contact the study team
- Brandon J Webb, MD · Phone: 801-507-7781
- Whitney R Buckel, PharmD · Phone: 801-284-1046
Official record on ClinicalTrials.gov — NCT07376889
Locations in the U.S.
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.